Related Experiment Video

Updated: Oct 2, 2025

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors
10:28

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors

Published on: August 17, 2019

9.8K

Mechanistically Coupled PK (MCPK) Model to Describe Enzyme Induction and Occupancy Dependent DDI of Dabrafenib

Marco Albrecht1,2, Yuri Kogan3, Dagmar Kulms4

  • 1Systems Biology Group, Department of Life Science and Medicine, Université du Luxembourg, 4367 Belvaux, Luxembourg.

Pharmaceutics
|February 26, 2022
PubMed

Insights

Dabrafenib resistance in melanoma may stem from drug accumulation, not just dose. Long-term dabrafenib use can increase metabolite levels, potentially hindering its effectiveness against BRAF-mutated melanoma.

Area of Science:

  • Pharmacology
  • Oncology
  • Biochemistry

Background:

  • Dabrafenib is a BRAF inhibitor for metastatic melanoma.
  • Monotherapy leads to pERK reactivation, resistance, and relapse.
  • High dabrafenib doses (>300 mg) increase pERK levels.

Purpose of the Study:

  • To investigate dabrafenib accumulation and its impact on efficacy.
  • To model pharmacokinetic interactions of dabrafenib and its metabolites.
  • To assess the effect of long-term dabrafenib exposure on melanoma cell death.

Main Methods:

  • Developed a Mechanistically Coupled Pharmacokinetics (MCPK) model.
  • Model integrated in vitro and clinical data.
  • Experimental validation using 451LU melanoma spheroids.

Main Results:

  • MCPK model predicted an eight-fold increase in desmethyl-dabrafenib concentration within four weeks at 150 mg b.d.
  • High dabrafenib concentrations did not induce cell death in melanoma spheroids.
  • CYP3A4 enzyme induction and drug-drug interactions were modeled.

Conclusions:

  • Long-term dabrafenib accumulation, not just dose, may drive resistance.
  • Metabolite buildup could reduce therapeutic efficacy in BRAF-mutated melanoma.
  • Further research into pharmacokinetic-pharmacodynamic relationships is warranted.
Keywords:
CYP3A4DDIMCPKPKdabrafenibenzyme inductionenzyme kineticsmetabolism

More Related Videos

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

581
A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.7K

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
102
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.3K
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
1.1K
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs01:21

Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs

A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in...
455
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
99
Induced-fit Model01:13

Induced-fit Model

Most chemical reactions in cells require enzymes—biological catalysts that speed up the reaction without being consumed or permanently changed. They reduce the activation energy needed to convert the reactants into products. Enzymes are proteins, that usually work by binding to a substrate—a reactant molecule that they act upon.
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
83.2K